The $15 billion expansion of the Roche-Hansoh partnership signals a massive shift toward multi-program antibody-drug conjugate portfolios rather than traditional single-asset licensing deals. This momentous agreement, finalized in late 2026, represents a fundamental restructuring of how global
Decision-curve analysis suggests that multiparametric MRI fusion models provide a higher clinical net benefit than current standard-of-care preoperative staging methods. In 2026, the landscape of gynecological oncology continues to evolve away from a one-size-fits-all surgical approach, moving
Manufacturing failures can occur if patients receive lymphodepleting agents like bendamustine too close to the collection of their therapeutic T cells. This biological reality creates a high-stakes environment for oncologists managing relapsed/refractory multiple myeloma, where the timing of every
Regulatory hurdles and the complexity of characterizing nanoparticle behavior in humans have slowed the progress of bone-targeted nanomedicines. Despite these significant challenges, osteosarcoma remains a primary concern in pediatric oncology due to its high rate of metastasis and the persistent
A personalized cancer vaccine puts manufacturing directly on the patient’s treatment timeline. Each medicine needs its own production and testing pathway, with the link to its intended recipient preserved throughout. Healthcare organizations and drug developers need an operating model that handles
The persistent challenge of treating advanced HPV16-positive malignancies has driven medical science toward a more personalized approach that prioritizes early detection of treatment efficacy through minimally invasive methods. In the current landscape of oncology, researchers are increasingly